CytomX Therapeutics CTMX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's free cash flow margin?
- CytomX Therapeutics (CTMX) reported free cash flow margin of -225.6% in Q1 2026.
- How has CytomX Therapeutics's free cash flow margin changed year-over-year?
- CytomX Therapeutics's free cash flow margin decreased by 308.3% year-over-year, from -55.3% to -225.6%.
- What is the long-term trend for CytomX Therapeutics's free cash flow margin?
- Over 4 years (2021 to 2025), CytomX Therapeutics's free cash flow margin has grown at a -25.5% compound annual growth rate (CAGR), from -323.3% to -99.5%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.